Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5915274 | 1.00 | MEN1 (0.57) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL8319217 | 0.79 | TTR (0.40) | — | |
| SCHEMBL8314276 | 0.79 | TTR (0.40) | — | |
| SCHEMBL9957328 | 0.79 | — | — | |
| SCHEMBL8314590 | 0.79 | TTR (0.40) | — | |
| SCHEMBL4896738 | 0.78 | MEN1 (0.52) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL1853258 | 0.77 | MEN1 (0.67) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL10526453 | 0.76 | MEN1 (0.57) | MEN1KMT2AKDM4EGAACYP2C9 | |
| SCHEMBL3300 | 0.76 | — | — | |
| SCHEMBL25148109 | 0.76 | MEN1 (1.00) | MEN1KMT2AKDM4EGAACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087573-A1 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-05-06 | — | — | US | claimed |
| US-20080004314-A1 | Phenylpiperidines and Phenylpyrrolidines | APODACA RICHARD L | 2008-01-03 | — | — | US | disclosed |
| US-7279491-B2 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-09 | — | — | US | disclosed |
| EP-1556046-A1 | PHENYLPIPERIDINES AND PHENYLPYRROLIDINES AS HISTAMINE H3 RECEPTOR MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004037257-A1 | PHENYLPIPERIDINES AND PHENYLPYRROLIDINES AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-05-06 | — | — | WO | disclosed |
| US-20040087573-A1 | Phenylpiperidines and phenylpyrrolidines | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087573-A1 | Phenylpiperidines and phenylpyrrolidines | HRH2, HNMT, HRH3 | MEN1 3148/4885KMT2A 2582/4885KDM4E 2587/4885 |
| US-20080004314-A1 | Phenylpiperidines and Phenylpyrrolidines | HRH2, HNMT, HRH3 | MEN1 3148/4885KMT2A 2582/4885KDM4E 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.